Weight-loss company Noom pivots to smaller doses of compounded Wegovy – CTV
May 20, 2025
Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk’s Wegovy as the U.S. drugs regulator clamps down on mass production of copies of the in-demand medicine.
Noom will offer its version of compounded semaglutide – the active ingredient in Wegovy and diabetes drug Ozempic – as part of a program personalized for patients, which it says will comply with changing U.S. Food and Drug Administration regulations.
Demand for the new generation of highly effective but pricey weight-loss drugs has catapulted sales at Noom and rival telehealth sites including Hims & Hers HIMS.N, WeightWatchers and Ro over the past two years.
Taking small doses of the weight-loss drugs, sometimes referred to as micro-dosing, has become popular due to the high cost and side effects of the medicines.
For hundreds of dollars less than the name brand drugs, patients could access doctors and pharmacy-made versions based on semaglutide or tirzepatide, the main ingredient in Eli Lilly’s LLY.N rival Zepbound and Mounjaro, due to a regulatory exception allowing them during drug shortages.
